COMBINATION THERAPY AND RELATED METHODS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 17, 2024
app pub date -
Feb 6, 2024
filing date -
Feb 6, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided herein are methods comprising the use of KRAS (e.g., hKRAS) inhibitors in combination with an agent(s) that specifically binds to EGFR (e.g., hEGFR) and TGFβ (e.g., hTGFβ), as well as compositions and kits comprising the same. The methods provided herein are useful in methods of treating cancer, (e.g., KRAS (e.g., hKRAS) variant cancers). Further provided herein are combination regimens, combination compositions, pharmaceutical compositions, and kits comprising a KRAS (e.g., hKRAS) inhibitor and an agent(s) that specifically binds to EGFR (e.g., hEGFR) and TGFβ (e.g., hTGFβ).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully